Patents by Inventor Christopher TenHoor

Christopher TenHoor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20240124593
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Application
    Filed: July 6, 2023
    Publication date: April 18, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • Antibodies which bind Fc receptors (FcRn)
    Patent number: 11739152
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: August 29, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • ASSAYS FOR DETERMINING PLASMA KALLIKREIN SYSTEM BIOMARKERS
    Publication number: 20220291232
    Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
    Type: Application
    Filed: December 20, 2021
    Publication date: September 15, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
  • Assays for determining plasma kallikrein system biomarkers
    Patent number: 11372002
    Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 28, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
  • EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS
    Publication number: 20220170936
    Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
    Type: Application
    Filed: October 1, 2021
    Publication date: June 2, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman, Yung Chyung
  • Methods of determining levels of cleaved and/or intact kininogen
    Patent number: 11156612
    Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: October 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman, Yung Chyung
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20210309741
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Application
    Filed: March 17, 2021
    Publication date: October 7, 2021
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
    Patent number: 11084884
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: August 10, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Ryan Iarrobino, Joseph Biedenkapp
  • Nucleic acids encoding anti-neonatal Fc receptor (FcRn) antibodies
    Patent number: 11014988
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: May 25, 2021
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • PLASMA KALLIKREIN BINDING PROTEINS AND USES THEREOF IN TREATING HEREDITARY ANGIOEDEMA
    Publication number: 20210087293
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Application
    Filed: September 2, 2020
    Publication date: March 25, 2021
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Ryan Iarrobino, Joseph Biedenkapp
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20200109199
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Application
    Filed: October 7, 2019
    Publication date: April 9, 2020
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • Fc receptor antibodies and methods of use thereof
    Patent number: 10479834
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: November 19, 2019
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20180305454
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Application
    Filed: December 4, 2017
    Publication date: October 25, 2018
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • Methods of producing antibodies to neonatal Fc receptor (FcRn)
    Patent number: 9862768
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: January 9, 2018
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
  • PLASMA KALLIKREIN BINDING PROTEINS AND USES THEREOF IN TREATING HEREDITARY ANGIOEDEMA
    Publication number: 20170002094
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Application
    Filed: January 21, 2015
    Publication date: January 5, 2017
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Rayan larrobino, Joe Biedenkapp
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160304608
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Application
    Filed: April 27, 2016
    Publication date: October 20, 2016
    Inventors: Daniel J. SEXTON, Christopher TENHOOR, Malini VISWANATHAN
  • ASSAYS FOR DETERMINING PLASMA KALLIKREIN SYSTEM BIOMARKERS
    Publication number: 20160252527
    Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
    Type: Application
    Filed: October 17, 2014
    Publication date: September 1, 2016
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222109
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 29, 2015
    Publication date: August 4, 2016
    Applicants: Dyax Corp., Biogen Hemophilia Inc.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222108
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 22, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222110
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 29, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan